111 related articles for article (PubMed ID: 12614245)
1. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?
Brown CT; O'Flynn E; Van Der Meulen J; Newman S; Mundy AR; Emberton M
BJU Int; 2003 Jan; 91(1):30-2. PubMed ID: 12614245
[TBL] [Abstract][Full Text] [Related]
2. An exploration of screening practices for prostate cancer and the associated community expenditure.
Perkins JJ; Sanson-Fisher RW; Clarke SJ; Youman P
Br J Urol; 1998 Oct; 82(4):524-9. PubMed ID: 9806181
[TBL] [Abstract][Full Text] [Related]
3. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
4. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
6. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
Godley PA; Carpenter WR
J Clin Epidemiol; 2007 Feb; 60(2):176-80. PubMed ID: 17208124
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
[TBL] [Abstract][Full Text] [Related]
8. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KN; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
BJU Int; 2008 Dec; 102(11):1629-33. PubMed ID: 18710456
[TBL] [Abstract][Full Text] [Related]
10. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening behavior in men from seven ethnic groups: the fear factor.
Consedine NS; Morgenstern AH; Kudadjie-Gyamfi E; Magai C; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):228-37. PubMed ID: 16492909
[TBL] [Abstract][Full Text] [Related]
12. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
14. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
15. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
17. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
19. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
[TBL] [Abstract][Full Text] [Related]
20. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]